NASDAQ:SVRA - Savara Stock Price, Forecast & News

Savara trades on the NASDAQ under the ticker symbol "SVRA."

Savara Inc (NASDAQ:SVRA) posted its quarterly earnings data on Thursday, November, 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.14. View Savara's Earnings History.

Savara is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Savara.

6 brokerages have issued 1-year price targets for Savara's stock. Their forecasts range from $1.00 to $17.00. On average, they expect Savara's stock price to reach $8.60 in the next year. This suggests a possible upside of 275.5% from the stock's current price. View Analyst Price Targets for Savara.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Savara.

Media coverage about SVRA stock has been trending somewhat negative on Thursday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Savara earned a news impact score of -1.7 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Savara.

Savara saw a increase in short interest in January. As of January 31st, there was short interest totalling 1,700,000 shares, an increase of 160.9% from the January 15th total of 651,500 shares. Based on an average trading volume of 1,687,700 shares, the short-interest ratio is presently 1.0 days. Approximately 6.1% of the company's stock are short sold. View Savara's Current Options Chain.

Some companies that are related to Savara include Avid Bioservices (CDMO), Fulcrum Therapeutics (FULC), Galera Therapeutics (GRTX), Dynavax Technologies (DVAX), Lannett (LCI), INDIVIOR PLC/S (INVVY), Rigel Pharmaceuticals (RIGL), DURECT (DRRX), Xenon Pharmaceuticals (XENE), Recro Pharma (REPH), Mallinckrodt (MNK), Verrica Pharmaceuticals (VRCA), Corbus Pharmaceuticals (CRBP), Concert Pharmaceuticals (CNCE) and CytomX Therapeutics (CTMX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BIOLINERX LTD/S (BLRX), CEL-SCI (CVM), Agile Therapeutics (AGRX), Sorrento Therapeutics (SRNE), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Trevena (TRVN), Verastem (VSTM), vTv Therapeutics (VTVT) and Geron (GERN).

Savara's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (12.45%), Farallon Capital Management LLC (11.71%), EcoR1 Capital LLC (3.48%), Point72 Asset Management L.P. (2.16%), Geode Capital Management LLC (1.06%) and Jacobs Levy Equity Management Inc. (0.81%). Company insiders that own Savara stock include David A Ramsay, David L Lowrance, Jaakko Taneli Jouhikainen, Richard J Hawkins, Robert N Neville and Yuri Pikover. View Institutional Ownership Trends for Savara.

SVRA stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp and Bank of America Corp DE. Company insiders that have sold Savara company stock in the last year include David L Lowrance, Jaakko Taneli Jouhikainen and Richard J Hawkins. View Insider Buying and Selling for Savara.

SVRA stock was purchased by a variety of institutional investors in the last quarter, including Bain Capital Life Sciences Investors LLC, EcoR1 Capital LLC, Farallon Capital Management LLC, Point72 Asset Management L.P., Jacobs Levy Equity Management Inc., Renaissance Technologies LLC, Acadian Asset Management LLC and Geode Capital Management LLC. Company insiders that have bought Savara stock in the last two years include David A Ramsay, Robert N Neville and Yuri Pikover. View Insider Buying and Selling for Savara.

Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SVRA stock can currently be purchased for approximately $2.29.

Savara has a market capitalization of $94.37 million. The company earns $-61,520,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. View Additional Information About Savara.

The official website for Savara is http://www.savarapharma.com/.

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, Austin TX, 78746. The company can be reached via phone at 512-961-1891 or via email at [email protected]